Stereotaxis, Inc.

AMEX:STXS

Medical - Instruments & Supplies

Healthcare
$0.95 +2.53%

+$0.05 today

Market cap
$94.80M
Beta
1.32
P/E (TTM)
-8.3
EPS (TTM)
-$0.22
52W Low $1.70High $3.59

Volume 0.90M

Average 0.39M

STXS Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Stereotaxis, Inc.AMEX: STXS

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns positive

Q1 FY2026 accounts receivables was $543K, compared with -$500K a year earlier. Trailing-twelve-month accounts receivables was -$980K.

Context

  • Accounts receivables amounted to 6.2% of revenue in FY2025, up 3.7 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $543K or moves back toward the trailing-twelve-month quarterly average of -$245K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$543K+205.6% QoQ
Last fiscal yearDec 2025
-$2.02M-392.8% YoY
LTMMar 2026
-$980K-404.3% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+208.6%——
1 year-392.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(2.02M) USD
Year-over-year change
-392.8%

Accounts Receivables vs competitors

How STXS compares with its peers on the latest reported figures

  • STXS's LTM Mar 2026 accounts receivables of $980K is the 3rd largest of the 5 companies compared; the peer median is $1.62M.
  • Its year-over-year change of -404.3% is the lowest of 4, against a peer median of +159.8%.
  • Accounts receivables amounts to 3.1% of revenue for STXS, versus a peer median of 18.9%.
STXS Competitors Peer median
Accounts Receivables for STXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SSIISS Innovations International, Inc.LTM Mar 2026$14.56M +1796.8%+131.9%30.0%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$3.13M +159.8%+8.3%7.7%
STXSStereotaxis, Inc.LTM Mar 2026$980K -404.3%—3.1%
NPCENeuroPace, Inc.LTM Mar 2026$647K +117.0%+67.3%0.7%
MBOTMicrobot Medical Inc.LTM Mar 2026$105K ——100.0%
Peer median (excluding STXS) $1.62M+159.8%+67.3%18.9%

Competitors are the stored peer set for STXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(10.72M)(18.29M)(20.71M)(24.05M)(21.64M)
Depreciation & Amortization106K429K595K969K1.56M
Deferred Income Tax00000
Stock-Based Compensation9.36M10.58M10.62M10.26M9.85M
Change in Working Capital135K(1.1M)612K2.51M(5.62M)
Accounts Receivables(1.89M)316K1.27M691K(2.02M)
Inventory(1.14M)(2.91M)(550K)677K(1.24M)
Accounts Payables1.43M(169K)218K758K(880K)
Other Working Capital1.73M1.66M(324K)379K(1.48M)
Other Non-Cash Items(1.83M)(25K)(256K)1.81M2.17M
Operating Cash Flow(2.95M)(8.42M)(9.14M)(8.5M)(13.69M)
Capital Expenditures(1.4M)(2.38M)(366K)(34K)(93K)
Acquisitions (Net)000108K0
Purchases of Investments0(19.72M)000
Sales of Investments0020.13M00
Other Investing Activities00000
Investing Cash Flow(1.4M)(22.09M)19.77M74K(93K)
Debt Repayment00000
Common Stock Issued547K220K81K297K14.76M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow547K220K81K297K14.76M
Effect of Forex Changes00000
Net Change in Cash(3.8M)(30.29M)10.71M(8.13M)985K
Free Cash Flow(4.34M)(10.79M)(9.51M)(8.53M)(13.78M)

Stereotaxis, Inc.

AMEX:STXS

Intrinsic Alpha fair value

Locked

Current Price

$0.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.